Rummel 2010.

Methods	Allocation generation: not reported Allocation concealment: not reported Blinding: no ITT: no Number of dropouts: 11/219 Median follow‐up: 33 months
Participants	219 randomised, 208 evaluable, adult patients Type of lymphoma: follicular lymphoma, mantle cell lymphoma, lymphoplasmacytic lymphoma, other indolent lymphoma Stage: 93% of patients allocated to bendamustine and 86% allocated to fludarabine stage III/IV Previous treatment: yes Mean age: 68 years (range 38 to 87 years)
Interventions	Investigational intervention: Bendamustine 90 mg/m2 on days 1 to 2, and rituximab 375 mg/m2 on day 1; every 4 weeks, up to 6 cycles Comparator intervention: Fludarabine 25 mg/m2 on days 1 to 3 and rituximab 375 mg/m2 on day 1; every 4 weeks, up to 6 cycles
Outcomes	Progression‐free survival Overall survival
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	"219 patients ... were randomized ...11 patients were not evaluable due to protocol violations, and were not followed further" Allocation of non‐evaluable patients is not reported
Selective reporting (reporting bias)	Low risk	Analyses were done as stated in protocol
Other bias	Unclear risk	Published as an abstract
Blinding of participants and personnel (performance bias) All outcomes	High risk	Participants and personnel were not blinded to allocated treatment
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported

CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone 
 CLL: chronic lymphocytic leukaemia 
 CR: complete response 
 ITT: intention‐to‐treat 
 iv: intravenous 
 PR: partial response 
 SLL: small lymphocytic lymphoma